Arcellx, Inc. (ACLX)

Arcellx's stock price has been significantly impacted by the definitive agreement for its acquisition by Gilead Sciences, Inc. In February 2026, Gilead Sciences announced its intent to acquire Arcellx in an all-cash tender offer valuing Arcellx at an implied $7.8 billion. In January 2026, Arcellx's lead CAR T-cell therapy, anito-cel, demonstrated strong positive clinical data in its pivotal Phase 2 iMMagine-1 study. Following the acquisition announcement, several analysts downgraded Arcellx's stock to "Hold" or "Neutral". Gilead extended its tender offer deadline to April 24, 2026. Arcellx reported an EPS of -$1.01, meeting analyst estimates, but revenue of $1.65 million missed expectations of $13.4 million in Q4 2025. The stock has seen a significant gain of 102.7% over the past 12 months.

As a clinical-stage biotechnology company focused on developing therapies for serious diseases like cancer, Arcellx, Inc. does not experience traditional demand seasonality for its products and services. The demand for its product candidates is driven by medical need, clinical trial progress, regulatory approvals, and eventual commercialization, rather than seasonal fluctuations. The company's revenue streams primarily come from collaborations and licensing agreements, and in the future, product sales, which are not typically seasonal in the pharmaceutical and biotechnology industries.

Arcellx, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other incurable diseases, operating within the Healthcare sector, specifically in the Biotechnology industry. Arcellx leverages its proprietary D-Domain, ddCAR, and ARC-SparX platforms to engineer next-generation cell therapies. Its major product candidate is Anitocabtagene autoleucel (anito-cel), a BCMA-targeting ddCAR product in Phase II and Phase III trials for relapsed or refractory multiple myeloma. Other product candidates include ACLX-001 and ACLX-002, both ARC-SparX programs in Phase I trials, targeting BCMA in rrMM and CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), respectively. The company is also developing preclinical programs for solid tumors and ACLX-003 and ACLX-004 for AML and MDS.

Arcellx, Inc. is headquartered in Redwood City, California, and conducts manufacturing operations at its facility in Malvern, Pennsylvania. The company plans to expand its international clinical trials into Europe and Asia-Pacific.

Arcellx's brand reputation in the past year appears to be largely positive, driven by its scientific advancements and strategic corporate developments. The strong positive clinical data from the Phase 2 iMMagine-1 study for anito-cel has bolstered its reputation. The acquisition by Gilead Sciences underscores confidence in Arcellx's technology and pipeline. Arcellx and Kite expanded their existing partnership, with Kite exercising its option to negotiate a license for Arcellx's ARC-SparX program, ACLX-001, and expanding the collaboration to include lymphomas. While there was a market reaction to preliminary trial results from a competitor, Citi attributed this to an "exaggerated market response".

Arcellx, Inc. has a high level of institutional ownership, with 221 institutional owners and shareholders holding a total of 61,400,863 shares. Major institutional owners include Gilead Sciences Inc., T. Rowe Price Investment Management Inc., and Vanguard Group Inc. Gilead Sciences Inc. is also noted as the largest individual Arcellx shareholder, owning 6.72 million shares, representing 11.49% of the company. Institutional shareholders hold 113.92% of Arcellx stock, while Arcellx insiders hold 101.74%, and retail investors hold 0.00%.